Already existing and proven drugs have a lot of untouched potential. But, not everyone can tap into the potential of these drugs, which is where $AGN.C comes in. $AGN.C is essentially a drug re-purposing company that investigates stable, already approved drugs for new disease applications, moving them efficiently into new human trials, developing new formulations, and seeking new regulatory approvals for markets. Their current line of drug research includes ifenprodil (IPF), DMT, and repirinast. With multiple phase 1 and 2 studies on the horizon, there's definitely a lot of potential for the company considering the recent price action and future catalysts as research remains ongoing.
- The DMT study (for DMTs use on stroke victims) has retained the Centre for Human Drug Research and its affiliated pharmacy at the Leiden University Medical Center in the Netherlands. Phase 1 will begin in September.
- Once the Repirinast cGMP synthesis is completed (for treatment of Chronic Kidney Disease). When completed the sub-acute toxicology study, the Company plans to begin a small Phase 1 study in Q4.
- Topline data from the Phase 2 study will be available in July (for the recently completed Ifenprodil Chronic Cough research study).
Now, I want to focus back on the chronic cough study as a number of patients have requested an ongoing supply of Ifenprodil for their personal use beyond the study’s treatment period.
Additionally, they also received a patent for using Ifenprodil to treat interstitial lung disease. These results really show the potential and how the company is continually moving forward with their extensive set of drug candidates. Plus, COVID has greatly increased the need for better chronic cough medication, which places $AGN.C in a solid position as COVID is most likely something that isn't going away anytime soon. Overall, the company is severely undervalued at these levels. Only a $5M market cap, and considering that they have numerous drugs nearing Phase 1 and in Phase 2 (alongside a recent $1.2M raise), there's a lot to consider here. I definitely will be keeping a close eye out for future results and the topline data from that Phase 2 study I mentioned above.